SeekIn launches LeukoPrint molecular karyotyping test in Europe

SeekIn is ready to launch its LeukoPrint molecular karyotyping test in European markets after receiving CE Mark approval.

The new kit, intended for the diagnosis of leukemias, was designed to identify copy number aberration (CNA) patterns in leukemia patients based on shallow whole genome sequencing (sWGS).

It can also assist hematologists in diagnosis and prognostic stratification according to the guidelines of European Leukemia Net (ELN), Revised International Prognostic Scoring System (IPSS-R) or Revised International Staging System (R-ISS).

Leukemias are a collection of malignant disorders of the blood and bone marrow that can occur at any age.

Additionally, LeukoPrint is suitable for many other forms of hematological malignancies, such as multiple myeloma.

SeekIn Founder and CEO Mao Mao said, “With the advent of new DNA sequencing technologies, next-generation sequencing (NGS)-based genetic testing has been implemented as a protocol routine for cancer diagnosis, risk stratification and assessment of response to treatment.

“LeukoPrint provides a cost-effective and simplified method for rapid and accurate ANC profiling in patients with leukemia. He used a standardized protocol, which can be easily extended to clinical laboratories around the world.

“With the advantage of detecting NACs from short DNA fragments, integrating with routine diagnostic methods, LeukoPrint can benefit from conventional cytogenetics by improving diagnostic yield.”

The company additionally expects to receive regulatory approvals in other territories, such as China.

He says the new test offers high accuracy and sensitivity and can help patients avoid the pain of having to give multiple bone marrow samples.

LeukoPrint also makes molecular subtyping, prognostic stratification, and treatment response monitoring accurate and comprehensive.

Related companies

Leave a Comment